These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27461380)

  • 41. XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides.
    Hori S; Yamamoto T; Obika S
    Biochem Biophys Res Commun; 2015 Aug; 464(2):506-11. PubMed ID: 26159921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next-Generation Peptide Nucleic Acid Chimeras Exhibit High Affinity and Potent Gene Silencing.
    Debacker AJ; Sharma VK; Meda Krishnamurthy P; O'Reilly D; Greenhill R; Watts JK
    Biochemistry; 2019 Feb; 58(6):582-589. PubMed ID: 30520300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Down-regulation of VEGF mRNA expression by 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression.
    Morita K; Yamate K; Kurakata S; Abe K; Imanishi T; Koizumi M
    Nucleic Acids Res Suppl; 2002; (2):99-100. PubMed ID: 12903124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis.
    Garcia JP; Stein J; Cai Y; Riemers F; Wexselblatt E; Wengel J; Tryfonidou M; Yayon A; Howard KA; Creemers LB
    J Control Release; 2019 Jan; 294():247-258. PubMed ID: 30572032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
    Jepsen JS; Pfundheller HM; Lykkesfeldt AE
    Oligonucleotides; 2004; 14(2):147-56. PubMed ID: 15294077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
    Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
    Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides.
    Anderson BA; Freestone GC; Low A; De-Hoyos CL; Iii WJD; Østergaard ME; Migawa MT; Fazio M; Wan WB; Berdeja A; Scandalis E; Burel SA; Vickers TA; Crooke ST; Swayze EE; Liang X; Seth PP
    Nucleic Acids Res; 2021 Sep; 49(16):9026-9041. PubMed ID: 34417625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA-Gapmer Approach.
    Wojtyniak M; Schmidtgall B; Kirsch P; Ducho C
    Chembiochem; 2020 Nov; 21(22):3234-3243. PubMed ID: 32662164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
    Iwashita S; Shoji T; Koizumi M
    Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
    Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
    J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
    Mook OR; Baas F; de Wissel MB; Fluiter K
    Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury.
    Moreno PMD; Ferreira AR; Salvador D; Rodrigues MT; Torrado M; Carvalho ED; Tedebark U; Sousa MM; Amaral IF; Wengel J; Pêgo AP
    Mol Ther Nucleic Acids; 2018 Jun; 11():393-406. PubMed ID: 29858074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How RNase HI (Escherichia coli) promoted site-selective hydrolysis works on RNA in duplex with carba-LNA and LNA substituted antisense strands in an antisense strategy context?
    Plashkevych O; Li Q; Chattopadhyaya J
    Mol Biosyst; 2017 May; 13(5):921-938. PubMed ID: 28352859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
    Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells.
    Fazil MH; Ong ST; Chalasani ML; Low JH; Kizhakeyil A; Mamidi A; Lim CF; Wright GD; Lakshminarayanan R; Kelleher D; Verma NK
    Sci Rep; 2016 Nov; 6():37721. PubMed ID: 27883055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals.
    Seth PP; Jazayeri A; Yu J; Allerson CR; Bhat B; Swayze EE
    Mol Ther Nucleic Acids; 2012 Sep; 1(10):e47. PubMed ID: 23344239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern.
    Hagedorn PH; Yakimov V; Ottosen S; Kammler S; Nielsen NF; Høg AM; Hedtjärn M; Meldgaard M; Møller MR; Orum H; Koch T; Lindow M
    Nucleic Acid Ther; 2013 Oct; 23(5):302-10. PubMed ID: 23952551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and Properties of Oligonucleotides Having Ethynylphosphonate Linkages.
    Horiba M; Yamaguchi T; Obika S
    J Org Chem; 2020 Feb; 85(4):1794-1801. PubMed ID: 31867976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.